Daxor Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Rhea-AI Summary

Daxor (Nasdaq: DXR), the global leader in blood volume measurement technology, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event will take place from September 9-11, 2024 at the Lotte New York Palace Hotel in New York City.

CEO and President Michael Feldschuh will deliver a presentation, which will be available on-demand starting September 9, 2024, at 7:00 AM ET. Investors can register for the conference to access the presentation. Additionally, Mr. Feldschuh will be available for one-on-one meetings with registered investors at the conference venue.

Interested investors can contact Bret Shapiro at CORE IR by calling 1-516-222-2560 or emailing brets@coreir.com for more information or to schedule meetings.

Oak Ridge, TN, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today that CEO and President Michael Feldschuh will present at the H.C. Wainwright 26th Annual Global Investment Conference being held on September 9-11, 2024 in New York City at the Lotte New York Palace Hotel.

The presentation will be available on-demand beginning September 9, 2024 at 7:00 AM ET.

Investors who wish to listen to the Company’s presentation can do so by registering for the conference here:
https://hcwevents.com/annualconference/

Mr. Feldschuh will be available for one-on-one meetings at the conference venue with registered investors of the conference.

Interested investors may also contact Bret Shapiro at CORE IR either by calling 1-516-222-2560 or emailing brets@coreir.com.

About Daxor Corporation

Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100^™ (Blood Volume Analyzer), the only diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com. Sign up to receive news on Daxor’s innovative technology HERE.

Forward-Looking Statements

Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact:
Bret Shapiro
Sr. Managing Partner, CORE IR
1-516-222-2560
brets@coreir.com

FAQ

When and where is Daxor (DXR) presenting at the H.C. Wainwright Global Investment Conference?

Daxor (DXR) will present at the H.C. Wainwright 26th Annual Global Investment Conference held from September 9-11, 2024, at the Lotte New York Palace Hotel in New York City. The on-demand presentation will be available starting September 9, 2024, at 7:00 AM ET.

How can investors access Daxor 's (DXR) presentation at the H.C. Wainwright conference?

Investors can access Daxor 's (DXR) presentation by registering for the conference at https://hcwevents.com/annualconference/. The presentation will be available on-demand beginning September 9, 2024, at 7:00 AM ET.

Who will be presenting on behalf of Daxor (DXR) at the H.C. Wainwright conference?

Michael Feldschuh, CEO and President of Daxor (DXR), will be presenting at the H.C. Wainwright 26th Annual Global Investment Conference.

Can investors schedule one-on-one meetings with Daxor (DXR) at the H.C. Wainwright conference?

Yes, CEO Michael Feldschuh will be available for one-on-one meetings with registered investors at the conference venue. Interested investors can contact Bret Shapiro at CORE IR to schedule meetings.

What is Daxor 's (DXR) main business focus?

Daxor (DXR) is described as the global leader in blood volume measurement technology.